Human Anti-IL-23 Antibodies, Compositions, Methods and Uses
AssigneeJanssen Biotech, Inc.
InventorsJacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet
Life of this patent
Estimating the term…
Abstract
A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
Claims10
A prefilled syringe containing a liquid pharmaceutical formulation of an isolated IL-23p19 antibody, comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:
- a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:50;
- a CDRL2 amino acid sequence of SEQ ID NO:56;
- and
- a CDRL3 amino acid sequence of SEQ ID NO:73,
- said heavy chain variable region comprising:
- a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:5;
- a CDRH2 amino acid sequence of SEQ ID NO:20;
- and
- a CDRH3 amino acid sequence of SEQ ID NO:44.
A prefilled syringe containing a liquid pharmaceutical formulation of an antibody comprising at least one member selected from the group consisting of a light chain variable region having the amino acid sequence of SEQ ID NO:116, a heavy chain variable region having the amino acid sequence of SEQ ID NO:106, and a heavy chain variable region having the amino acid sequence of SEQ ID NO:106 with up to three substitutions from residues 50-66 of the amino acid sequence of SEQ ID NO:
- 106.
A prefilled syringe containing a liquid pharmaceutical formulation of an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO:116 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:106.
The prefilled syringe of claim 9, wherein the liquid pharmaceutical formulation comprises L-histidine, L-histidine monohydrocloride monohydrate, sucrose, polysorbate 80 and water.
A prefilled syringe containing a liquid pharmaceutical formulation of an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO:116, a heavy chain variable region having the amino acid sequence of SEQ ID NO:106, wherein the liquid pharmaceutical formulation comprises L-histidine, L-histidine monohydrocloride monohydrate, sucrose, polysorbate 80 and water and the pH of the formulation is about 5.8.
Dependencies are inferred from the claim text.